Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Journal of Clinical Investigation

Volumn 127, Issue 4, 2017, Pages 1425-1437

  Kohanbash, Gary ^a   Carrera, Diego A ^a   Shrivastav, Shruti ^a   Ahn, Brian J ^b   Jahan, Naznin ^a   Mazor, Tali ^a   Chheda, Zinal S ^a   Downey, Kira M ^a   Watchmaker, Payal B ^a   Beppler, Casey ^c   Warta, Rolf ^d   Amankulor, Nduka A ^b   Herold Mende, Christel ^d   Costello, Joseph F ^a   Okada, Hideho ^a,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 5; ISOCITRATE DEHYDROGENASE; SHORT HAIRPIN RNA; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VACCINE; CANCER VACCINE; CHEMOKINE; IDH1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL STIMULATION; CHROMOSOME 19Q; CHROMOSOME 1P; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GLIOMA; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LONG TERM SURVIVAL; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TISSUE SECTION; UPREGULATION; VACCINATION; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMOTAXIS; CYTOTOXIC T LYMPHOCYTE; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 85018710344     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90644     Document Type: Article

References (61)

1. Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71-95.
2. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
3. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115(5):948-965.
4. Cancer Genome Atlas Research Network, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498.
5. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 2012;29(3):131-139.
6. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
7. Johnson BE, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
8. Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
9. Lin Y, Okada H. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016;16(10):1265-1275.
10. Reardon DA, et al. Mitchell DA, Fecci PE, Sampson JH, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013;12(6):597-615.
11. Nishimura F, et al. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006;66(8):4478-4487.
12. Fujita M, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008;180(4):2089-2098.
13. Fujita M, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res. 2009;69(4):1587-1595.
14. Fujita M, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664-2674.
15. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumourinfiltrating lymphocytes from human gliomas. Clin Exp Immunol. 1996;105(2):344-352.
16. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev. 1995;21(2):128-151.
17. Nitta T, Hishii M, Sato K, Okumura K. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res. 1994;649(1-2):122-128.
18. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-?-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177(2):896-904.
19. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer. 2005;92(5):921-928.
20. Ahn BJ, Pollack IF, Okada H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013;5(4):1379-1412.
21. Kohanbash G, Okada H. Myeloid-derived suppressor cells in gliomas and glioma-development. Immunol Invest. 2012;41(6-7):658-679.
22. Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(suppl 7):vii9-vii14.
23. Elkhaled A, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra5.
24. Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
25. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. 2009;117(6):653-656.
26. Pavon LF, et al. In vitro analysis of neurospheres derived from glioblastoma primary culture: a novel methodology paradigm. Front Neurol. 2014;4:214.
27. Jaruga B, Hong F, Kim WH, Gao B. IFN-?/STAT1 acts as a proinflammatory signal in T cellmediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol. 2004;287(5):G1044-G1052.
28. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421.
29. Ueda R, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of gliomaassociated antigen peptide vaccines. Clin Cancer Res. 2009;15(21):6551-6559.
30. Hatano M, et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004;2(1):40.
31. Zhu X, et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-? and IFN-? dependent manners. Cancer Immunol Immunother. 2010;59(9):1401-1409.
32. Okada H, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330-336.
33. Johannessen TA, et al. Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. Mol Cancer Res. 2016;14(10):976-983.
34. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
35. Kosaka A, Ohkuri T, Okada H. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces antiglioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother. 2014;63(8):847-857.
36. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
37. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970;30(9):2394-2400.
38. Eckel-Passow JE, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508.
39. Sharma P, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscleinvasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104(10):3967-3972.
40. Kmiecik J, et al. Elevated CD3+ and CD8+ tumorinfiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1-2):71-83.
41. Lohr J, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-?. Clin Cancer Res. 2011;17(13):4296-4308.
42. Arita H, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016;4(1):79.
43. Wen Z, Zhong Z, Darnell JE. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82(2):241-250.
44. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol. 1997;159(2):794-803.
45. Gil MP, Salomon R, Louten J, Biron CA. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood. 2006;107(3):987-993.
46. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998;95(26):15623-15628.
47. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.
48. Ohba S, et al. Mutant IDH1 expression drives TERT promoter reactivation as part of the cellular transformation process. Cancer Res. 2016;76(22):6680-6689.
49. Prins RM, Graf MR, Merchant RE. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother. 2001;50(6):285-292.
50. Xiao Z, Mescher MF, Jameson SC. Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med. 2007;204(11):2667-2677.
51. Beck BH, et al. Dynamics of circulating T cell activity in an immunocompetent mouse model of high-grade glioma. PLoS One. 2015;10(5):e0122387.
52. Chang AL, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671-5682.
53. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949.
54. Schumacher T, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324-327.
55. Giannakis M, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;17(4):1206.
56. Bouffet E, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206-2211.
57. Okada H, et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015;21(2):286-294.
58. Kalinina J, et al. Detection of oncometabolite 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med. 2012;90(10):1161-1171.
59. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. 2014;74(17):4836-4844.
60. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284-287.
61. Kohanbash G, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-?. Cancer Res. 2013;73(21):6413-6423.